产品
编 号：F719386
分子式：C31H39N11O6S
分子量：693.78
分子式：C31H39N11O6S
分子量：693.78
产品类型
规格
价格
是否有货
结构图
CAS No: 957471-96-4
产品详情
生物活性：
D13-9001 is a potent AcrB (AcrAB-TolC efflux pump subunit) and MexB (MexAB-OprM efflux pump subunit) inhibitor with the KD values of 1.15 μM and 3.57 μM in E. coli and P. aeruginosa, respectively. D13-9001 exhibits antibiotic activities.
体内研究：
D13-9001 (1.25-20 mg/kg; intravenous drip infusion; 2 hours) with aztreonam (AZT) gives improved survival rates in a lethal pneumonia rats at the end of day seven compared with AZT treated alone.Animal Model:SD rats (Pulmonary infection by P. aeruginosa PAM1020)
Dosage:1.25 mg/kg, 5 mg/kg, 20 mg/kg
Administration:Intravenous drip infusion; 2 hours
Result:The combination of 1.25, 5, and 20 mg/kg of D13-9001 with 1000 mg/kg of AZT gave improved survival rates at the end of day seven, whereas no obvious effect was observed on treatment with AZT alone.
体外研究：
D13-9001 exhibits high solubility and a good safety profile.
D13-9001 is a potent AcrB (AcrAB-TolC efflux pump subunit) and MexB (MexAB-OprM efflux pump subunit) inhibitor with the KD values of 1.15 μM and 3.57 μM in E. coli and P. aeruginosa, respectively. D13-9001 exhibits antibiotic activities.
体内研究：
D13-9001 (1.25-20 mg/kg; intravenous drip infusion; 2 hours) with aztreonam (AZT) gives improved survival rates in a lethal pneumonia rats at the end of day seven compared with AZT treated alone.Animal Model:SD rats (Pulmonary infection by P. aeruginosa PAM1020)
Dosage:1.25 mg/kg, 5 mg/kg, 20 mg/kg
Administration:Intravenous drip infusion; 2 hours
Result:The combination of 1.25, 5, and 20 mg/kg of D13-9001 with 1000 mg/kg of AZT gave improved survival rates at the end of day seven, whereas no obvious effect was observed on treatment with AZT alone.
体外研究：
D13-9001 exhibits high solubility and a good safety profile.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备